Conference Programme
BioTrinity takes place over two full days: April 15-16, 2008, in Oxford, UK, and includes several concurrent elementsas well as informal networking and an exhibition:- One-to-one Partnering
- Panel Discussions on VC, M&A and Partnering
- Company Showcase
- Technology Showcase
- Workshops
- Bio-IT Showcase
Download a portable programme for BioTrinity in Adobe PDF format.
Jump to Programme summary for each day
Tuesday 15th April 2008 - BioTrinity 2008 Programme for Day OneWednesday 16th April 2008 - BioTrinity 2008 Programme for Day Two
Programme Overview
|
Preliminary Programme
| Tuesday 15th April 2008 - BioTrinity 2008 - Oxford - Day One | |
| 08:00-08:50 | Registration and Breakfast |
| 08:50-09:00 | Welcome & Opening Remarks, Dr. Jon Rees, Network Director, OBN |
| 09:00-09:05 | Harriet Fear, Team Leader, Biotech & Pharma Team, UKTI |
| 09:05-09:25 | Plenary Talk: Strategic development of a sustainable medium-sized biopharmaceutical company: Commercialisation of TroVax and ProSavin - Peter Nolan, SVP Commercial Development, Oxford BioMedica |
| 09:25-09:45 | David Phillips, SVP, Sales and Marketing,
BioFocus DPI Building a leading European Biotechnology Company |
| 09:45-10:30 | Panel Discussion: How to Realise Value in Biotech Partnering & Financing (Oxford Suite) |
| Charles Macfarlane, Non-Executive Director,
PharmaVentures Ltd Shaun Grady, Vice President Deal Management, Strategic Planning and Business Development, AstraZeneca (UK) Charlie Alexander, Director of Business Development, Shire Pharmaceuticals (UK) Edwin Moses, Chairman & CEO, Ablynx (Belgium) Dr Kevin J. Scanlon, Founder & CEO, International Bioscience (US) | |
| 10:30-11:00 | Refreshments, Networking and Exhibition |
| 11:00-11:45 | Panel Discussion: Financing Alternatives in a Challenging Economy: IPO, M&A and Other Non-dilutive Financing |
|
This financing discussion will have a global perspective on one of the
biggest biotech financing issues of the day. | |
| 11.45-12.00 | Company Showcase (Oxford Suite) |
| 12:00-13:00 | Lunch, Networking and Exhibition over upper and lower floors of Quadrangle |
| Two parallel sessions will run during the afternoon | |
| 13.00-16.00 | Company Showcase (Oxford Suite) continued... |
| Drug discovery and development company showcase. The most promising companies showcase features 25 companies from the South East of England selected on the basis of their fundraising or revenue streams, USP, deal-making, innovation, and IP. The focus is on drug discovery and development, bioprocessing and diagnostics. Click here to find out which companies are presenting. | |
| 13.00-16.00 | Technology Showcase (Spires Room) |
| The technology showcase features young spin out companies, candidate spin-outs and technology licensing opportunities from the South East UK, including Isis Innovation, selected on merit. Click here to find out which companies and tech transfer organisations are presenting. | |
| 16.15-16.30 | Key Notes on the Growth and Development of the Sector - The Oxford BioCluster (Oxford Suite) |
| OBN BioCluster Report - An Executive Summary. Find out more about the OBN BioCluster Report 2008 | |
| 16:30-18:00 | Networking Reception Sponsored by UKTI - Launch of Cluster Report 2008 |
| All delegates are welcome to join the networking receptions on Tuesday and Wednesday | |
| Wednesday 16th April 2008 - BioTrinity 2008 - Oxford - Day Two | |
| 08:00-08:50 | Registration and Breakfast |
| 08:50-09:00 | Welcome and Announcement of Winner of OBN Preferred Lab Supplier Tender, Jon Rees and Chris Locke, OBN |
| 09:00-9.40 | VC Panel Discussion: Creating Opportunities to Exit a Biotech Business Earlier (Oxford Suite) |
|
Key Notes and Panel Discussion from US, EU and Corporate Venturers who
have invested in companies and alliances involving the UK's biotechnology
and healthcare industry | |
| 09:40-10:00 | The Deal Making Dance - Licensing, Partnering and Strategic Alliances (Oxford Suite) |
| Lubor Gaal, Director, Licensing Europe, External Science Technology & Licensing, Bristol-Myers Squib | |
| 10:00-10:10 | Key Developments: Reaching Critical Mass (Oxford Suite) |
| Rick de Blaby, CEO, MEPC describes the next wave of affordable grow-on space for biotech companies in the Oxford BioCluster | |
| 10.10-10.30 | Company Showcase (Oxford Suite) |
| 10.30-11.00 | Refreshments, Networking and Exhibition |
| Two parallel sessions will run during the remainder of the day | |
| 11.00-12.00 | Company Showcase continued... |
| Drug discovery and development company showcase. The most promising companies showcase features 25 companies from the South East of England selected on the basis of their fundraising or revenue streams, USP, deal-making, innovation, and IP. Click here to find out which companies are presenting. | |
| 10.30-12.00 | Technology Showcase (Spires Room) |
| The technology showcase features young spin out companies, candidate spin-outs and technology licensing opportunities from the South East UK, including Isis Innovation, selected on merit. Click here to find out which companies and tech transfer organisations are presenting. | |
| 12:00-13:00 | Lunch, Networking and Exhibition over upper and lower floors of Quadrangle - sponsored by Stimutran SME |
| 13:00-14:00 | Panel Discussion: European GMP Biomanufacturing: Is Bigger More Beautiful (Oxford Suite) |
|
This discussion will feature several European biomanufacturers and will
be chaired by an internationally reknowned expert, considering difference
between US and European best practice in GMP Biomanufacturing. | |
| 14.00-16.00 | Company Showcase continued... (Oxford Suite) |
| Drug discovery and development, diagnostics and medical technology company showcase. The most promising companies showcase features 25 companies from the South East of England selected on the basis of their fundraising or revenue streams, USP, deal-making, innovation, and IP. Click here to find out which companies are presenting. | |
| 13.00-16.00 | Bio-IT Showcase (Spires Room) |
| The Bio-IT Showcase is a unique forum for delegates from R&D companies to meet the informatics solutions providers which are addressing some of the most pressing and problematic issues facing pharmaceutical and biotechnology companies in the drug discovery pipeline. Click here to find out which companies are presenting. | |
| 16.00-17.00 | Conference Close Drinks and Networking Reception, sponsored by Merck Sharp & Dohme |
| All delegates are welcome to join the networking receptions on Tuesday and Wednesday | |
Deadlines for Speakers
| 1 Apr 2008 | Speaker/Presenter deadline for submitting PowerPoint presentations - see OBN Contact details. |
To whet your appetite here are some of the speakers which will form part of the 50+ taking part in the panel discussions, company showcases and workshops:
Director of Business Development, Shire Pharma
Principal (Life Sciences), Atlas Venture
Partner (Life Sciences), Sofinnova Partners
Investment Director, Oxford Capital Partners
Merck Sharp Dohme (Director, Scientific Liason)
CEO, Solace Pharma
CEO, Glide Pharma
CEO, Chemocentryx
CEO, Celleron Therapeutics
CEO, Phynova
EVP Business Development, Evotec
CEO, Hybrid Systems
CEO, Summit plc
CEO, (OSI) Prosidion
CEO, Oxford Genome Sciences
CEO, G-Nostics
Director, Lein Applied Diagnostics
CEO, Oxford BioMaterials
CEO, Syntaxin
Business Research and Development Manager, Biocompatibles
Charles McFarlane, Non-Executive Director, PharmaVentures
Look at the growing list of Companies Attending BioTrinity 2008
PROJECT PARTNERS
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
